Sugi Predict

Sugi Predict / Compounds / SCHEMBL521422

SCHEMBL521422

SCHEMBL521422

COC(=O)c1ccc(C=Cc2ccccc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.67
▸ PTPN1 P18031 1/20 0.65
▸ ALDH1A1 P00352 2/20 0.63
▸ CA1 P00915 2/20 0.63
▸ CA2 P00918 2/20 0.63
▸ HDAC1 Q13547 1/20 0.61
▸ RAB9A P51151 6/20 0.58
▸ NPC1 O15118 5/20 0.58
▸ MAPT P10636 6/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ CASP3 P42574 1/20 0.58
▸ SENP8 Q96LD8 1/20 0.58
▸ SENP7 Q9BQF6 1/20 0.58
▸ SENP6 Q9GZR1 1/20 0.58
▸ LMNA P02545 3/20 0.57
▸ MAOB P27338 1/20 0.55
▸ POLB P06746 2/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL521421 1.00 TSHR (0.67) TSHRPTPN1ALDH1A1CA1CA2
(Z)-1,2-Diphenylethene SCHEMBL1604066 0.94 TSHR (0.76) TSHRPTPN1ALDH1A1CA1CA2
(Z)-1,2-Diphenylethene SCHEMBL1604067 0.94 TSHR (0.76) TSHRPTPN1ALDH1A1CA1CA2
SCHEMBL13899902 0.93 TSHR (0.62) TSHRPTPN1ALDH1A1CA1CA2
SCHEMBL2627847 0.92 PTPN1 (0.73) TSHRPTPN1ALDH1A1CA1CA2
SCHEMBL5379059 0.92 PTPN1 (0.73) TSHRPTPN1ALDH1A1CA1CA2
SCHEMBL71402 0.92 PTPN1 (0.73) TSHRPTPN1ALDH1A1CA1CA2
SCHEMBL71401 0.92 PTPN1 (0.73) TSHRPTPN1ALDH1A1CA1CA2
SCHEMBL31301140 0.92 PTPN1 (0.73) TSHRPTPN1ALDH1A1CA1CA2
SCHEMBL7532835 0.91 EGFR (0.60) TSHRPTPN1ALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1763509-B1 ALPHA-HELICAL MIMETICS WALTER & ELIZA HALL INST MEDICAL RES (AU) 2018-02-21 — — EP disclosed
EP-2417082-B1 CATALYTIC WITTIG AND MITSUNOBU REACTIONS UNIV TEXAS (US) 2016-03-16 — — EP disclosed
CN-102438970-B Wittig reaction and the light of catalysis prolong reaction BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) 2015-10-14 — — CN disclosed
US-8901365-B2 Catalytic Wittig and Mitsunobu reactions BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-12-02 — — US disclosed
EP-2417082-A2 CATALYTIC WITTIG AND MITSUNOBU REACTIONS THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-02-15 — — EP disclosed
US-20120029211-A1 Catalytic Wittig and Mitsunobu Reactions THE UNIVERSITY OF TEXAS AT ARLINGTON 2012-02-02 — — US disclosed
US-7956216-B2 Benzoyl urea derivatives mimicing BH3-only proteins, able to interact with a Bcl-2 protein THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2011-06-07 — — US disclosed
WO-2010118042-A2 CATALYTIC WITTIG AND MITSUNOBU REACTIONS BOARD OF REGENTS THE UNIVERSITY OF TEXAS AT ARLINGTON (US) 2010-10-14 — — WO disclosed
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 — — US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 — — US disclosed
US-6720338-B2 BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL ABBOTT LABORATORIES 2004-04-13 — — US disclosed
EP-1318978-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2003-06-18 — — EP disclosed
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters ABBVIE INC. 2002-07-04 — — US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 — — US disclosed
WO-2002024636-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2002-03-28 — — WO disclosed
CN-1293680-A Method for producing aqueous polymer dispersions containing colorants BASF AG (DE) 2001-05-02 — — CN disclosed
CN-1209147-A Soil release polymers with fluorescent whitening properties PROCTER & GAMBLE (US) 1999-02-24 — — CN disclosed
EP-0032432-B1 PROSTANOID COMPOUNDS AND THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS GLAXO GROUP LIMITED (GB) 1985-07-24 — — EP disclosed
US-4438112-A PROSTAGLANDINS, ANTICOAGULANTS, ANTIASTHMA GLAXO GROUP LIMITED (GB) 1984-03-20 — — US disclosed
EP-0032432-A1 Prostanoid compounds and their preparation and pharmaceutical formulations GLAXO GROUP LIMITED (GB) 1981-07-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086887-A1 N-Acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 TSHR 4377/4885PTPN1 2196/4885ALDH1A1 2651/4885
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 TSHR 4350/4885PTPN1 2547/4885ALDH1A1 2460/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR TSHR 4129/4885PTPN1 2831/4885ALDH1A1 3404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.